close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

17.01 -0.45 (-2.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 994,771
Open 17.32
Bid (Size) 17.00 (2,100)
Ask (Size) 17.01 (8,000)
Prev. Close 17.46
Today's Range 16.99 - 17.53
52wk Range 9.820 - 20.06
Shares Outstanding 103,647,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Overlooked Stocks Set to Soar in 2026 ↗
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks. 
Via The Motley Fool
News headline image
NovoCure (NVCR) Q1 2026 Earnings Transcript ↗
NovoCure (NVCR) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Supply Chain

Performance

YTD
+29.6%
+29.6%
1 Month
+34.3%
+34.3%
3 Month
+52.8%
+52.8%
6 Month
+50.9%
+50.9%
1 Year
-5.3%
-5.3%

More News

Read More
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
Novocure (NASDAQ: NVCR) Q1 Revenue Beat and Path to Profitability Drive 9% Share Jump ↗
Via Chartmill
Novocure Ltd (NASDAQ:NVCR) Reports Mixed Q4 2025 Results, Stock Falls on Revenue Miss ↗
Via Chartmill
News headline image
Novocure Reports First Quarter 2026 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure to Report First Quarter 2026 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
From Novocure
Via Business Wire
News headline image
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
News headline image
Novocure to Participate in 2026 Leerink Global Healthcare Conference
From Novocure
Via Business Wire
News headline image
NovoCure (NVCR) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings World Trade
News headline image
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
From Novocure
Via Business Wire
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
From Novocure
Via Business Wire
News headline image
Soleus Adds a Significant Number of Celcuity Shares ↗
Via The Motley Fool
AI: The Great Disruptor or the Great Divider? ↗
Via Chartmill
News headline image
NVCR Rallies On FDA Approval For Cancer Treatment Device, Analyst Still Sees 275% Potential Upside ↗
Via Stocktwits
Topics Government
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation
Via Finterra
Topics Initial Public Offering Intellectual Property
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Novocure Stock Surges Nearly 30% After Hours: FDA Clears First New Pancreatic Cancer Therapy In Almost Three Decades ↗
Via Stocktwits
News headline image
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
From Novocure
Via Business Wire
News headline image
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
From Novocure
Via Business Wire

Frequently Asked Questions

Is NovoCure Limited - Ordinary Shares publicly traded?
Yes, NovoCure Limited - Ordinary Shares is publicly traded.
What exchange does NovoCure Limited - Ordinary Shares trade on?
NovoCure Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for NovoCure Limited - Ordinary Shares?
The ticker symbol for NovoCure Limited - Ordinary Shares is NVCR on the Nasdaq Stock Market
What is the current price of NovoCure Limited - Ordinary Shares?
The current price of NovoCure Limited - Ordinary Shares is 17.01
When was NovoCure Limited - Ordinary Shares last traded?
The last trade of NovoCure Limited - Ordinary Shares was at 05/19/26 04:00 PM ET
What is the market capitalization of NovoCure Limited - Ordinary Shares?
The market capitalization of NovoCure Limited - Ordinary Shares is 1.76B
How many shares of NovoCure Limited - Ordinary Shares are outstanding?
NovoCure Limited - Ordinary Shares has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today